Previous close | 10.84 |
Open | 10.81 |
Bid | 10.53 x 200 |
Ask | 10.55 x 7100 |
Day's range | 10.37 - 10.93 |
52-week range | 6.97 - 13.24 |
Volume | |
Avg. volume | 6,718,349 |
Market cap | 8.494B |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | 2.00 |
EPS (TTM) | 5.27 |
Earnings date | 26 Jun 2024 - 01 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.08 |
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the completion of a near-term milestoneBatoclimab produced positive results in Graves’ disease with response rates meaningfully exceeding 50% in the initial cohort of an ongoing 24